Iana R. Orshanskaya

Iana R. Orshanskaya

Auto-generated profile, based on publicly available information

Iana R. Orshanskaya

Smorodintsev Research Institute of Influenza, St. Petersburg 197376, Russia

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 April 2021 in Molecules
Verified
Journal Article
Open access
PDF file
ASAnastasiya Sokolova
Anastasiya Sokolova
VPValentina Putilova
Valentina Putilova
Olga I. YarovayaOlga I. Yarovaya
Olga I. Yarovaya
AZAnastasiya V. Zybkina
Anastasiya V. Zybkina
EMEkaterina Mordvinova
Ekaterina Mordvinova
NSNariman F. Salakhutdinov
Nariman F. Salakhutdinov
To date, the ‘one bug-one drug’ approach to antiviral drug development cannot effectively respond to the constant threat posed by an increasing diversity of viruses causing outbreaks of viral infections that turn out to be pathogenic for humans. Evidently, there is an urgent need for new strategies to develop efficient antiviral agents with broad-spectrum activities. In this paper, we identified camphene derivatives that showed broad antiviral activities in vitro against a panel of enveloped pathogenic viruses, including influenza virus A/PR/8/34 (H1N1), Ebola virus (EBOV), and the Hantaan virus. The lead-compound 2a, with pyrrolidine cycle in its structure, displayed antiviral activity against influenza virus (IC50 = 45.3 µM), Ebola pseudotype viruses (IC50 = 0.12 µM), and authentic EBOV (IC50 = 18.3 µM), as well as against pseudoviruses with Hantaan virus Gn-Gc glycoprotein (IC50 = 9.1 µM). The results of antiviral activity studies using pseudotype viruses and molecular modeling suggest that surface proteins of the viruses required for the fusion process between viral and cellular membranes are the likely target of compound 2a. The key structural fragments responsible for efficient binding are the bicyclic natural framework and the nitrogen atom. These data encourage us to conduct further investigations using bicyclic monoterpenoids as a scaffold for the rational design of membrane-fusion targeting inhibitors.

1 October 2015 in Bioorganic & Medicinal Chemistry
Verified
Journal Article
Closed access
CTConstantin Tanase
Constantin Tanase
CDConstantin Drăghici
Constantin Drăghici
ACAna Cojocaru
Ana Cojocaru
AGAnastasia V. Galochkina
Anastasia V. Galochkina
JOJana R. Orshanskaya
Jana R. Orshanskaya
MMMaria Maganu
Maria Maganu

30 June 2022 in Molecules
Verified
Journal Article
Open access
PDF file
VKVictor Krasnov
Victor Krasnov
VMVera V. Musiyak
Vera V. Musiyak
GLGalina L. Levit
Galina L. Levit
DGDmitry Gruzdev
Dmitry Gruzdev
VAValeria Andronova
Valeria Andronova
Valery N. CharushinValery N. Charushin
Valery N. Charushin
A series of pyrimidine conjugates containing a fragment of racemic 7,8-difluoro-3,4-dihydro-3-methyl-2H-[1,4]benzoxazine and its (S)-enantiomer attached via a 6-aminohexanoyl fragment were synthesized by the reaction of nucleophilic substitution of chlorine in various chloropyrimidines. The structures of the synthesized compounds were confirmed by 1H, 19F, and 13C NMR spectral data. Enantiomeric purity of optically active derivatives was confirmed by chiral HPLC. Antiviral evaluation of the synthesized compounds has shown that the replacement of purine with a pyrimidine fragment leads to a decrease in the anti-herpesvirus activity compared to the lead compound, purine conjugate. The studied compounds did not exhibit significant activity against influenza A (H1N1) virus.

28 May 2025 in Antibodies
Verified
Journal Article
Open access
PDF file
ARAlexandra Rak
Alexandra Rak
BEBazhenova Ekaterina
Bazhenova Ekaterina
PPPolina Prokopenko
Polina Prokopenko
VMVictoria Matyushenko
Victoria Matyushenko
YOYana Orshanskaya
Yana Orshanskaya
LRLarisa G. Rudenko
Larisa G. Rudenko
Cases of new COVID-19 infection, which manifested in 2019 and caused a global socioeconomic crisis, still continue to be registered worldwide. The high mutational activity of SARS-CoV-2 leads to the emergence of new antigenic variants of the virus, which significantly reduces the effectiveness of COVID-19 vaccines, as well as the sensitivity of diagnostic test systems based on variable viral antigens. These problems may be solved by focusing on highly conserved coronavirus antigens, for example nucleocapsid (N) protein, which is actively expressed by coronavirus-infected cells and serves as a target for the production of virus-specific antibodies and T cell responses. It is known that anti-N antibodies are non-neutralizing, but their protective potential and functional activity are not sufficiently studied. Here, the protective effect of anti-N antibodies was studied in Syrian hamsters passively immunized with polyclonal sera raised to N(B.1) recombinant protein. The animals were infected with 105 or 104 TCID50 of SARS-CoV-2 (B.1, Wuhan or BA.2.86.1.1.18, Omicron) 6 h after serum passive transfer, and protection was assessed by weight loss, clinical manifestation of disease, viral titers in the respiratory tract, as well as by the histopathological evaluation of lung tissues. The functional activity of anti-N(B.1) antibodies was evaluated by complement-dependent cytotoxicity (CDC) and antibody-dependent cytotoxicity (ADCC) assays. The protection of anti-N antibodies was evident only against a lower dose of SARS-CoV-2 (B.1) challenge, whereas almost no protection was revealed against BA.2.86.1.1.18 variant. Anti-N(B.1) monoclonal antibodies were able to stimulate both CDC and ADCC. Thus, anti-N(B.1) antibodies possess protective activity against homologous challenge infection, which is possibly mediated by innate Fc-mediated immune reactions. These data may be informative for the development of N-based broadly protective COVID-19 vaccines.

12 May 2025 in Preprints.org
Verified
Preprint
Open access
PDF file
ARAlexandra Rak
Alexandra Rak
BEBazhenova Ekaterina
Bazhenova Ekaterina
PPPolina Prokopenko
Polina Prokopenko
VMVictoria Matyushenko
Victoria Matyushenko
YOYana Orshanskaya
Yana Orshanskaya
LRLarisa G. Rudenko
Larisa G. Rudenko
Background/Objectives: Cases of the new COVID-19 coronavirus infection, which manifested in 2019 and caused a global socioeconomic crisis, still continue to be registered worldwide. The high mutational activity of SARS-CoV-2 leads to the emergence of new antigenic variants of the virus, which significantly reduces the effectiveness of COVID-19 vaccines, as well as the sensitivity of diagnostic test systems based on variable viral antigens. These problems may be solved by the focusing on highly conserved coronavirus antigens, for example nucleocapsid (N) protein, which is actively expressed by coronavirus-infected cells and serves as a target for the production of virus-specific antibodies and T-cell responses. It is known that anti-N antibodies are non-neutralizing, but their protective potential and functional activity are not sufficiently studied. Methods: Protective effect of anti-N antibodies was studied in Syrian hamsters passively immunized with polyclonal sera raised to N(B.1) recombinant protein. Animals were infected with 105 or 104 TCID50 of SARS-CoV-2 (B.1, Wuhan or BA.2.86.1.1.18, Omicron) 6 hours after serum passive transfer, and protection was assessed by weight loss, clinical manifestation of disease, viral titers in respiratory tract, as well as by histopathological evaluation of lung tissues. Functional activity of anti-N (B.1) antibodies was evaluated by complement-dependent cytotoxicity (CDC) and antibody-dependent cytotoxicity (ADCC) assays. Results: Protection of anti-N antibodies was evident only against lower dose of SARS-CoV-2 (B.1) challenge, whereas almost no protection was revealed against BA.2.86.1.1.18 variant. Anti-N (B.1) monoclonal antibodies were able to stimulate CDC and ADCC. Conclusions: Anti-N (B.1) antibodies possess protective activity against homologous challenge infection, which is possibly mediated by innate Fc-mediated immune reactions. These data may be informative for the development of N-based broadly-protective COVID-19 vaccines.